BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening - 2Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- 3Must-See Attractions in Washington, D.C.
- 44 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- 5The Solution to Flexibility: Developing Internal Fortitude Notwithstanding Misfortune
- Kansas school officials report high student illness, dismiss early
- Vote In favor of Your Favored Treat
- More parents refusing this shot that prevents serious bleeding at birth
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- How to see the Ursids, the final meteor shower of 2025
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- 3D Printers for Specialists
- UAE recalls some Nestle infant formula products, Qatar warns consumers
